FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083044356> ?p ?o ?g. }

• W2083044356 endingPage "1250" @default.
• W2083044356 startingPage "1248" @default.
• W2083044356 abstract "HomeCirculationVol. 112, No. 9Double Face of VEGF Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBDouble Face of VEGF Yoshiaki Tsutsumi, MD, PhD and Douglas W. Losordo, MD Yoshiaki TsutsumiYoshiaki Tsutsumi From the Division of Cardiovascular Research, St. Elizabeth Medical Center, Tufts University School of Medicine, Boston, Mass. Search for more papers by this author and Douglas W. LosordoDouglas W. Losordo From the Division of Cardiovascular Research, St. Elizabeth Medical Center, Tufts University School of Medicine, Boston, Mass. Search for more papers by this author Originally published30 Aug 2005https://doi.org/10.1161/CIRCULATIONAHA.105.566166Circulation. 2005;112:1248–1250The Roman god Janus (Figure) was the guardian of gates and doors and was believed to represent beginnings and endings; he is hence represented by a double-faced head. He particularly presided over all that is double-edged in life and represented the transition between the primitive and civilization, between the countryside and the city, peace and war, and the growing-up of young people. The controversy over vascular endothelial growth factor’s (VEGF) role in pathologic angiogenesis and the transition from a healthy to a diseased state is thus symbolized to a certain extent by the “gatekeeper” function that Janus played in Roman mythology. Download figureDownload PowerPointThe Roman god Janus.See p 1347The concept of angiogenesis as a disease pathophysiology was borne out of observations made by Folkman and colleagues regarding the enhanced vascularity of tumors. Folkman “simply” noted that tumors were bloodier than surrounding healthy tissues, positing that the tumors must have an auxiliary means of augmenting vessel growth to accommodate the expansion of unhealthy tissue. The Folkman laboratory then demonstrated that tumors produced substances capable of stimulating vessel growth,1 igniting an entirely new field of research. One of these angiogenic factors, of course, is VEGF, and the supporting role of VEGF in tumor growth has been established by the success of VEGF neutralizing antibody for the treatment of certain solid tumors in humans.2–4 VEGF expression has also been noted in human atherosclerotic plaque.5 Accordingly, the notion that VEGF may also be a key component of plaque growth is grounded in solid experimental and clinical science.For more than half a century the role of the periadventitial microvasculature, or vasa vasorum, in atherosclerosis has been the subject of study, scrutiny, and debate. The association between advancing plaque burden and extension of the vasa vasorum into the media was first made by Geiringer6 and was strengthened by studies by Williams and colleagues,7 revealing regression of the vasa in animal models of atherosclerosis regression. Kwon et al8 also provided evidence that adventitial neovascularization of vasa vasorum occurs in experimental hypercholesterolemic coronary arteries and may be a part of the early atherosclerotic remodeling process.The development of endothelial specific inhibitors then led to a provocative series of experiments by Moulton and coworkers that revealed that attenuation of the vasa vasorum, by administration of antiangiogenic agents, reduced the rate of fatty streak formation in ApoE-deficient mice.9 The reduction in plaque size was accompanied by reduced plaque vascularity, underscoring the intimate relationship between the vasa vasorum and neointimal lesion formation. Celletti et al extended this concept by administering recombinant human VEGF165 protein to cholesterol-fed New Zealand White rabbits10,11 or ApoE/ApoB100-deficient (ApoE−/−/ApoB48/48) mice,11 showing an increase in the rate and degree of fatty streak formation associated with an increase in the infiltration of macrophages in the thoracic aorta.The extrapolation of these observations has fueled concern that attempts at therapeutic neovascularization of ischemic tissue may promote plaque growth by driving angiogenesis in the vasa vasorum, thereby increasing rather than decreasing the overall ischemic burden.12 In contrast, however, human clinical trial experience has provided no evidence to support the concept that administration of angiogenic agents to patients with already advanced atherosclerosis will lead to disease progression.13–23 Although each of the clinical trials done to date has been relatively small, the cumulative experience now exceeds 1000 patients, with no evidence suggesting disease progression induced by administration of angiogenic agents.The disparate findings in the animal models versus human clinical trial experience raises multiple questions, among them the fidelity of animal models for human atherosclerosis. The study by Leppänen et al24 in this issue of Circulation precisely addresses this point. Using adenoviral gene transfer or recombinant VEGF protein administration, the authors document that VEGF exposure, even for prolonged periods, has no impact on atherosclerosis progression in the LDLR/ApoB48-deficient mouse model. The authors examined the progression of atherosclerosis in the aorta after intravenous administration of VEGF-A, -B, -C, -D, and lacZ expressing adenovirus or recombinant human VEGF-A protein. Human VEGF-A, -B, -C, and -D were detectable, peaking at 4 days and persisting for 4 to 6 weeks in the peripheral blood after adenoviral gene transfer. In contrast, the clearance of human VEGF-A protein was only 15 minutes after human VEGF-A protein injection. Human VEGF-A gene was expressed in the aorta at 4 to 10 times’ higher level than endogenous VEGF-A 5 days after VEGF-A adenovirus injection. These data are critically important when comparing the present study with previous studies in which VEGF protein was reported to augment plaque vascularity.10 In the present study, despite the prolonged exposure to increased VEGF levels, there were no significant differences in atherosclerotic lesion area, macrophage content, and interestingly, no increased neovascularization in the adventitia or atherosclerotic lesions in VEGF versus control mice.The first question that comes to mind is how to reconcile the results of the study by Leppänen et al with previous studies showing that VEGF could augment atherosclerotic plaque growth. The answer probably lies in differences between the animal models used. Celletti et al10,11 used ApoE−/−/ApoB48/48 mice, whereas Leppänen et al used LDLR−/−/ApoB100/100 mice. These mice were both developed by Young’s group25–27 and exhibit a plasma lipoprotein distribution that is significantly different despite having similar total plasma cholesterol levels.25–27 Specifically, the large-sized lipoprotein (VLDL) is 2-fold higher in ApoE−/−/ApoB48/48 mice. In contrast, nearly all cholesterol is LDL in the LDLR−/−/ApoB100/100 mice. Fazio et al28 showed that transplantation of apoE+/+/LDLR−/− bone marrow to apoE−/−/ LDLR−/− mouse significantly reduced atherosclerosis in apoE−/−/LDLR−/− mouse. Van Eck et al29 also revealed that transplantation of apoE−/− marrow to wild-type mice increased atherosclerosis lesions. These data strongly implicate ApoE expression in bone marrow–derived macrophages as having a major influence on atherosclerosis progression. Together, these features suggest that the LDLR−/−/ApoB100/100 mouse may be a preferable model of human atherosclerosis because of their lipoprotein distribution and natural macrophage environment.The more profound question raised by this study, however, is whether short-term exposure to angiogenic agents alone can accelerate atherosclerosis. The present data, in a suitable animal model, and the clinical experience to date, suggests that the answer is no. So, can we close the curtain on this debate? Clearly not. Mechanisms to explain the contrasting findings of the Leppänen et al study and its predecessors will continue to be the subject of intense scrutiny. More important, this study has illuminated the critical importance of animal model selection, study design, and data interpretation and the ultimate need for verifying hypotheses in the clinical setting. The potential for therapeutic benefit via modulation of angiogenesis is an established fact. Our caution in attempting therapeutic neovascularization in patients with intractable ischemia must be balanced against the ongoing harm and suffering inflicted by the disease itself, and must be informed by our continuously evolving understanding of the biology we are attempting to modulate. In this regard, Leppänen and colleagues have added important data, consistent with clinical observation, supporting the safety of continued development of these novel strategies for patients who have exhausted all available therapies.The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.FootnotesCorrespondence to Douglas W. Losordo, MD, St. Elizabeth’s Medical Center of Boston, 736 Cambridge St, Boston, MA 02135. E-mail [email protected] References 1 Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med. 1971; 133: 275–288.CrossrefMedlineGoogle Scholar2 Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349: 427–434.CrossrefMedlineGoogle Scholar3 Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335–2342.CrossrefMedlineGoogle Scholar4 Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004; 10: 145–147.CrossrefMedlineGoogle Scholar5 Couffinhal T, Kearney M, Witzenbichler B, Chen D, Murohara T, Losordo DW, Symes JF, Isner JM. Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries. Am J Pathol. 1997; 150: 1673–1685.MedlineGoogle Scholar6 Geiringer E. Intimal vascularization and atherosclerosis. J Pathol Bacteriol. 1951; 63: 201–211.CrossrefMedlineGoogle Scholar7 Williams JK, Armstrong ML, Heistad DD. Vasa vasorum in atherosclerotic coronary arteries: responses to vasoactive stimuli and regression of atherosclerosis. Circ Res. 1988; 62: 515–523.CrossrefMedlineGoogle Scholar8 Kwon HM, Sangiorgi G, Ritman EL, McKenna C, Holmes DR Jr, Schwartz RS, Lerman A. Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J Clin Invest. 1998; 101: 1551–6.CrossrefMedlineGoogle Scholar9 Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation. 1999; 99: 1726–1732.CrossrefMedlineGoogle Scholar10 Celletti FL, Hilfiker PR, Ghafouri P, Dake MD. Effect of human recombinant vascular endothelial growth factor165 on progression of atherosclerotic plaque. J Am Coll Cardiol. 2001; 37: 2126–2130.CrossrefMedlineGoogle Scholar11 Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med. 2001; 7: 425–429.CrossrefMedlineGoogle Scholar12 Ware JA, Simons M. Angiogenesis in ischemic heart disease. Nat Med. 1997; 3: 158–64.CrossrefMedlineGoogle Scholar13 Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg. 1998; 65: 1540–1544.CrossrefMedlineGoogle Scholar14 Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, Hachamovitch R, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, Isom OW, Crystal RG. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation. 1999; 100: 468–474.CrossrefMedlineGoogle Scholar15 Losordo DW, Vale PR, Hendel RC, Milliken CE, Fortuin FD, Cummings N, Schatz RA, Asahara T, Isner JM, Kuntz RE. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation. 2002; 105: 2012–2018.LinkGoogle Scholar16 Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervino EV, Pike M, Whitehouse MJ, Moon T, Chronos NA. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation. 2002; 105: 788–793.LinkGoogle Scholar17 Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ, Annex BH. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet. 2002; 359: 2053–2058.CrossrefMedlineGoogle Scholar18 Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD, West A, Rade JJ, Marrott P, Hammond HK, Engler RL. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation. 2002; 105: 1291–1297.CrossrefMedlineGoogle Scholar19 Comerota AJ, Throm RC, Miller KA, Henry T, Chronos N, Laird J, Sequeira R, Kent CK, Bacchetta M, Goldman C, Salenius JP, Schmieder FA, Pilsudski R. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg. 2002; 35: 930–936.CrossrefMedlineGoogle Scholar20 Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation. 2003; 107: 1359–1365.LinkGoogle Scholar21 Hedman M, Hartikainen J, Syvanne M, Stjernvall J, Hedman A, Kivela A, Vanninen E, Mussalo H, Kauppila E, Simula S, Narvanen O, Rantala A, Peuhkurinen K, Nieminen MS, Laakso M, Yla-Herttuala S. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation. 2003; 107: 2677–2683.LinkGoogle Scholar22 Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease: part I: angiogenic cytokines. Circulation. 2004; 109: 2487–2491.LinkGoogle Scholar23 Kastrup J, Jorgensen E, Ruck A, Tagil K, Glogar D, Ruzyllo W, Botker HE, Dudek D, Drvota V, Hesse B, Thuesen L, Blomberg P, Gyongyosi M, Sylven C. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol. 2005; 45: 982–988.CrossrefMedlineGoogle Scholar24 Leppänen P, Koota S, Kholová I, Koponen J, Fieber C, Eriksson U, Alitalo K, Ylä-Herttuala S. Gene transfers of vascular endothelial growth factor-A, vascular endothelial growth factor-B, vascular endothelial growth factor-C, and vascular endothelial growth factor-D have no effects on atherosclerosis in hypercholesterolemic low-density lipoprotein-receptor/apolipoprotein-receptor B48-deficient mice. Circulation. 2005; 112: 1347–1352.LinkGoogle Scholar25 Farese RV Jr, Veniant MM, Cham CM, Flynn LM, Pierotti V, Loring JF, Traber M, Ruland S, Stokowski RS, Huszar D, Young SG. Phenotypic analysis of mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. Proc Natl Acad Sci U S A. 1996; 93: 6393–6398.CrossrefMedlineGoogle Scholar26 Veniant MM, Zlot CH, Walzem RL, Pierotti V, Driscoll R, Dichek D, Herz J, Young SG. Lipoprotein clearance mechanisms in LDL receptor-deficient “Apo-B48-only” and “Apo-B100-only” mice. J Clin Invest. 1998; 102: 1559–1568.CrossrefMedlineGoogle Scholar27 Veniant MM, Withycombe S, Young SG. Lipoprotein size and atherosclerosis susceptibility in Apoe(−/−) and Ldlr(−/−) mice. Arterioscler Thromb Vasc Biol. 2001; 21: 1567–1570.CrossrefMedlineGoogle Scholar28 Fazio S, Babaev VR, Burleigh ME, Major AS, Hasty AH, Linton MF. Physiological expression of macrophage apoE in the artery wall reduces atherosclerosis in severely hyperlipidemic mice. J Lipid Res. 2002; 43: 1602–1609.CrossrefMedlineGoogle Scholar29 Van Eck M, Herijgers N, Vidgeon-Hart M, Pearce NJ, Hoogerbrugge PM, Groot PH, Van Berkel TJ. Accelerated atherosclerosis in C57Bl/6 mice transplanted with ApoE-deficient bone marrow. Atherosclerosis. 2000; 150: 71–80.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Polozova Anastasia V, Boyarinov Gennadii A, Nikolsky Viktor O, Zolotova Marina V and Deryugina Anna V (2021) The functional indexes of RBCs and microcirculation in the traumatic brain injury with the action of 2-ethil-6-methil-3-hydroxypiridin succinate, BMC Neuroscience, 10.1186/s12868-021-00657-w, 22:1, Online publication date: 1-Dec-2021. Kim L, Russkikh G, Putyatina A and Tsypysheva O (2021) Age-Related Features of the Relationship between the Content of Vascular Endothelial Growth Factor and the Parameters of the Lipid Metabolism and Extracellular Matrix Metabolism in Men of the European Part of the Russian Arctic, Advances in Gerontology, 10.1134/S2079057021010392, 11:1, (93-100), Online publication date: 1-Jan-2021. Ruzov V, Belogubov P, Butov A, Burmistrova V, Sharafutdinova R and Belogubova K (2020) VASCULAR ENDOTHELIAL GROWTH FACTOR AND MYOCARDIAL ELECTRICAL INHOMOGENEITY IN ALCOHOL-DEPENDENT YOUNG PEOPLE, Ulyanovsk Medico-biological Journal, 10.34014/2227-1848-2020-4-51-60:4, (51-60), Online publication date: 30-Dec-2021. Gavrilenko T, Ryzhkova N, Parkhomenko O and Dovgan N (2019) PHYSIOLOGICAL SIGNIFICANCE OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN PATIENTS WITH ACUTE FORMS OF CORONARY ARTERY DISEASE, Fiziolohichnyĭ zhurnal, 10.15407/fz65.05.033, 65:5, (33-39), Online publication date: 10-Oct-2019. Marette A and Sweeney G (2014) Cardiovascular complications of diabetes: recent insights in pathophysiology and therapeutics, Expert Review of Endocrinology & Metabolism, 10.1586/eem.11.63, 6:5, (689-696), Online publication date: 1-Sep-2011. Jargin S (2010) Shock wave therapy of ischemic heart disease in the light of general pathology, International Journal of Cardiology, 10.1016/j.ijcard.2008.12.198, 144:1, (116-117), Online publication date: 1-Sep-2010. Deguchi T, Hashiguchi T, Horinouchi S, Uto T, Oku H, Kimura K, Makisumi K and Arimura K (2009) Serum VEGF increases in diabetic polyneuropathy, particularly in the neurologically active symptomatic stage, Diabetic Medicine, 10.1111/j.1464-5491.2009.02680.x, 26:3, (247-252), Online publication date: 1-Mar-2009. Riazy M, Chen J and Steinbrecher U (2009) VEGF secretion by macrophages is stimulated by lipid and protein components of OxLDL via PI3-kinase and PKCζ activation and is independent of OxLDL uptake, Atherosclerosis, 10.1016/j.atherosclerosis.2008.08.004, 204:1, (47-54), Online publication date: 1-May-2009. Eaton C, Gramling R, Parker D, Roberts M, Lu B and Ridker P (2008) Prospective association of vascular endothelial growth factor-A (VEGF-A) with coronary heart disease mortality in Southeastern New England, Atherosclerosis, 10.1016/j.atherosclerosis.2007.12.027, 200:1, (221-227), Online publication date: 1-Sep-2008. González J and Andrés V (2006) Cytostatic gene therapy for occlusive vascular disease, Expert Opinion on Therapeutic Patents, 10.1517/13543776.16.4.507, 16:4, (507-522), Online publication date: 1-Apr-2006. Moulton K (2006) Angiogenesis in atherosclerosis: gathering evidence beyond speculation, Current Opinion in Lipidology, 10.1097/01.mol.0000245261.71129.f0, 17:5, (548-555), Online publication date: 1-Oct-2006. Piliponova V and Slobodianyk V (2019) РОЛЬ ЕНДОТЕЛІАЛЬНОЇ ДИСФУНКЦІЇ НИРОК В ПАТОГЕНЕЗІ ЗАХВОРЮВАНЬ ТА ЇХ УСКЛАДНЕНЬ, Здобутки клінічної і експериментальної медицини, 10.11603/1811-2471.2019.v.i3.10503:3, (32-39) August 30, 2005Vol 112, Issue 9 Advertisement Article InformationMetrics https://doi.org/10.1161/CIRCULATIONAHA.105.566166PMID: 16129810 Originally publishedAugust 30, 2005 Keywordsgrowth substancesgene therapyEditorialsPDF download Advertisement SubjectsAtherosclerosis" @default.
• W2083044356 created "2016-06-24" @default.
• W2083044356 creator A5031305752 @default.
• W2083044356 creator A5054665868 @default.
• W2083044356 date "2005-08-30" @default.
• W2083044356 modified "2023-10-11" @default.
• W2083044356 title "Double Face of VEGF" @default.
• W2083044356 cites W1561059299 @default.
• W2083044356 cites W1963497337 @default.
• W2083044356 cites W1969985246 @default.
• W2083044356 cites W1975519085 @default.
• W2083044356 cites W1987066539 @default.
• W2083044356 cites W2026662206 @default.
• W2083044356 cites W2046507292 @default.
• W2083044356 cites W2056148198 @default.
• W2083044356 cites W2075333521 @default.
• W2083044356 cites W2076202270 @default.
• W2083044356 cites W2095426703 @default.
• W2083044356 cites W2103227975 @default.
• W2083044356 cites W2109134893 @default.
• W2083044356 cites W2112804253 @default.
• W2083044356 cites W2120582139 @default.
• W2083044356 cites W2121342540 @default.
• W2083044356 cites W2124337564 @default.
• W2083044356 cites W2124715674 @default.
• W2083044356 cites W2125150769 @default.
• W2083044356 cites W2134563904 @default.
• W2083044356 cites W2138369468 @default.
• W2083044356 cites W2152843042 @default.
• W2083044356 cites W2157769714 @default.
• W2083044356 doi "https://doi.org/10.1161/circulationaha.105.566166" @default.
• W2083044356 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16129810" @default.
• W2083044356 hasPublicationYear "2005" @default.
• W2083044356 type Work @default.
• W2083044356 sameAs 2083044356 @default.
• W2083044356 citedByCount "17" @default.
• W2083044356 countsByYear W20830443562013 @default.
• W2083044356 countsByYear W20830443562014 @default.
• W2083044356 countsByYear W20830443562019 @default.
• W2083044356 countsByYear W20830443562020 @default.
• W2083044356 countsByYear W20830443562021 @default.
• W2083044356 countsByYear W20830443562022 @default.
• W2083044356 countsByYear W20830443562023 @default.
• W2083044356 crossrefType "journal-article" @default.
• W2083044356 hasAuthorship W2083044356A5031305752 @default.
• W2083044356 hasAuthorship W2083044356A5054665868 @default.
• W2083044356 hasBestOaLocation W20830443561 @default.
• W2083044356 hasConcept C126322002 @default.
• W2083044356 hasConcept C138885662 @default.
• W2083044356 hasConcept C167734588 @default.
• W2083044356 hasConcept C2779304628 @default.
• W2083044356 hasConcept C41895202 @default.
• W2083044356 hasConcept C71924100 @default.
• W2083044356 hasConceptScore W2083044356C126322002 @default.
• W2083044356 hasConceptScore W2083044356C138885662 @default.
• W2083044356 hasConceptScore W2083044356C167734588 @default.
• W2083044356 hasConceptScore W2083044356C2779304628 @default.
• W2083044356 hasConceptScore W2083044356C41895202 @default.
• W2083044356 hasConceptScore W2083044356C71924100 @default.
• W2083044356 hasIssue "9" @default.
• W2083044356 hasLocation W20830443561 @default.
• W2083044356 hasLocation W20830443562 @default.
• W2083044356 hasOpenAccess W2083044356 @default.
• W2083044356 hasPrimaryLocation W20830443561 @default.
• W2083044356 hasRelatedWork W1506200166 @default.
• W2083044356 hasRelatedWork W1995515455 @default.
• W2083044356 hasRelatedWork W2048182022 @default.
• W2083044356 hasRelatedWork W2080531066 @default.
• W2083044356 hasRelatedWork W2604872355 @default.
• W2083044356 hasRelatedWork W2748952813 @default.
• W2083044356 hasRelatedWork W2899084033 @default.
• W2083044356 hasRelatedWork W3031052312 @default.
• W2083044356 hasRelatedWork W3032375762 @default.
• W2083044356 hasRelatedWork W3108674512 @default.
• W2083044356 hasVolume "112" @default.
• W2083044356 isParatext "false" @default.
• W2083044356 isRetracted "false" @default.
• W2083044356 magId "2083044356" @default.
• W2083044356 workType "article" @default.